Some small molecular inhibitors of EGFR are also under investigation for the management of HNSCC, including selective inhibitors (e.g., gefitinib, erlotinib) (80, 81, 105, 106) and dual-target inhibitors (e.g., afatinib, lapatinib, and dacomitinib) (82, 107). This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.